GLP-3 RT is a synthetic peptide formulated with exceptionally high purity (≥ 99%) designed for in vitro and ex vivo research use only.
It functions as a “triple-agonist”—meaning it simultaneously activates the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCGR) receptors. This unique activity profile distinguishes it from single- or dual-agonist compounds and offers comprehensive insight into multiple metabolic pathways.
Key Features & Research Advantages
High Purity & Quality: Each 10 mg vial is manufactured to research-grade standards with HPLC and MS verification indicating ≥ 99% purity.
Advanced Mechanism of Action: By engaging GLP-1, GIP, and glucagon receptors concurrently, GLP-3 RT enables exploration of appetite regulation, energy expenditure, insulin sensitivity, and fat metabolism in one compound.
Applicability to Multiple Research Domains: Ideal for studies in weight-loss strategies, metabolic health, type 2 diabetes modeling, obesity research, lipid profile investigations, and even longevity or cardio-metabolic investigations.
